HEALTH: Summary of Oct 30, 2026

By · Published on

Illustration of glass medicine vials
AI-generated illustration; does not depict the actual event.

A blood test picked up returning lung cancer long before scans, an electronic implant lowered blood sugar in diabetic mice, Africa’s leading disease official warned that Ebola could spread far beyond the continent, a Congolese chief described fighting mistrust of care, and omega-3 pills failed to help memory.

Blood test spots signs of returning lung cancer months before scans, study finds

A blood test that looks for fragments of tumour DNA detected signs of returning lung cancer well before tumours could be seen on scans, according to a study by researchers at NYU Langone Health in New York. In 42 patients with early, stage IA lung adenocarcinoma, the test found tumour DNA in 9 of the 12 people whose cancer later came back, and in those cases it came up positive a median of 16.7 months before the relapse was confirmed.

The researchers reported a sensitivity of 75%, a specificity of 83% and a negative predictive value of 89%, meaning that patients with a negative result were very likely to stay in remission. The lead investigator said the findings were promising but must be confirmed in larger forward-looking studies before routine use. Experts noted that a negative result does not prove the cancer has gone, and that acting earlier has not yet been shown to improve survival.

Surgery can cure many people with early non-small cell lung cancer, the most common form of the disease, but the cancer returns in roughly a third of patients, and routine CT scans cannot find very small amounts of remaining disease. Tumours shed pieces of their genetic material into the bloodstream, and these traces can be measured through repeated blood draws, known as liquid biopsies, to follow how a cancer changes over the course of treatment.


Electronic implant lowers blood sugar and weight in diabetic mice without insulin

Researchers at ETH Zurich have built an implant that lowers blood sugar by turning glucose into a related compound called gluconate, much of which the kidneys then flush out, instead of delivering insulin or any drug. In mice with obesity and type 2 diabetes, running the device for 60 minutes a day kept glucose under control for at least six weeks, and the treated animals lost up to 10% of their body weight without eating less.

The team, led by Martin Fussenegger in Basel, published its results in the journal Science. The device uses an electrode coated with tiny gold structures dotted with platinum and draws power wirelessly from an external transmitter. When linked to a commercial glucose monitor, it switched itself on whenever readings rose too high, regulating levels automatically for 12 days and bringing sugar back to normal within roughly 60 to 90 minutes. It has not yet been tried in people.

Type 2 diabetes, marked by high blood sugar and resistance to insulin, accounts for about 90% of all diabetes cases and is driven mainly by obesity and a lack of exercise. Around 392 million people had been diagnosed with it by 2015. Treatment usually begins with exercise, changes in diet and medicines such as metformin, though many patients eventually need insulin injections, and those using insulin are often advised to track their glucose with a continuous monitor.


Africa’s top disease official warns the Ebola outbreak could reach Britain and beyond

The head of the Africa Centres for Disease Control and Prevention, Jean Kaseya, has warned that the Ebola outbreak centred on the Democratic Republic of the Congo could reach Britain and other countries, comparing it with the early spread of Covid. The outbreak, which passed 10,000 confirmed cases this week, now stands at 10,091 cases, of which 10,060 are in Congo, where 4,887 people have died. Two deaths have been recorded in Uganda and two in Kenya.

Kaseya said that for the first time three African regions had been affected, after Nigeria confirmed a case in Abuja in a woman who had arrived from Uganda. He urged governments to screen travellers at borders and said vaccine trial results could come within three to six months. Of $3bn pledged for the response, more than $2bn has not arrived, with African countries committing $120m. He also plans to seek a corridor of peace in conflict areas at a November summit.

The outbreak is caused by the Bundibugyo virus, named after the district in western Uganda where it was first found, which has no approved treatment and previously caused outbreaks in 2007 and 2012. It is the 17th outbreak in Congo since the disease was identified and the largest and deadliest in the country’s history. Congo declared the outbreak in Ituri province on 15 May, although genetic sequencing later showed that it had begun in February.


Congolese village chief battles Ebola mistrust after losing four relatives

Alphonse bin Kitobi Achou Taibo, chief of the Bapakombe-Bakondo village on the edge of Beni in eastern Congo, lost four family members to Ebola after relatives refused to go to hospital, accusing him of taking them there to die. Eleven other members of his extended family caught the virus and survived once he got them to treatment. He said the biggest obstacle was widespread mistrust, with many people likening Ebola to poison and some pastors linking it to evil spirits.

One cousin, 27-year-old Zawadi Kavira Musubao, fell ill at a funeral and was given a healer’s potion that made her worse, before she later recovered at hospital. Her landlord then forced her family out, claiming that disinfection had brought evil spirits into the house. Government figures from early October showed that more than 70% of new cases were outside known contact lists and at least 60% of deaths happened outside treatment centres.

Beni lies just west of Virunga National Park and was an epicentre of the 2018 to 2019 Kivu Ebola epidemic. It became the temporary capital of North Kivu province after the March 23 Movement captured Goma in 2025, and the current outbreak reached the city on 29 May 2026. Armed groups, including the Allied Democratic Forces, have long attacked the area, and the insecurity has limited health workers’ access to affected communities.


High-dose omega-3 supplements fail to protect memory in older adults at risk of Alzheimer’s

A two-year clinical trial led by researchers at Keck Medicine of USC found that a high daily dose of the omega-3 fatty acid DHA did not improve memory, thinking skills or brain structure in older adults at higher risk of Alzheimer’s disease. The study, published in the journal eBioMedicine, enrolled 365 adults without dementia aged 55 to 80, with an average age of 66, who took either 2,000 milligrams of DHA a day or a placebo.

The supplement raised DHA in the fluid around the brain and spinal cord by 17% and lifted participants’ blood omega-3 index from 4.9% to 11%, yet test scores and brain scans matched those of the placebo group. Of the volunteers, 225 completed the trial and 47% carried the APOE4 gene variant. An outside doctor said a two-year study may be too short to judge long-term protection, since the disease develops over decades.

DHA is the most abundant omega-3 fatty acid in the brain and retina and can be obtained from oily fish such as salmon, herring, mackerel and sardines, as well as from fish oil or algae oil. It makes up 40% of the polyunsaturated fats in the brain. In a federal survey covering 2017 and 2018, 21.8% of American adults aged 60 and over said they had taken an omega-3 supplement in the previous 30 days.

In this topic